Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype
EN,SE

People & Organization

Our Management

Executive Committee

Søren Tulstrup

President and Chief Executive Officer

Søren Tulstrup has broad and extensive experience as senior executive in the global biopharma industry. Before joining Hansa in 2018, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company. Søren Tulstrup has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical Company developing RNA-targeted drugs for various therapeutic areas including rare genetic diseases. Furthermore, Søren Tulstrup has served in several senior general management and commercial roles within Shire Pharmaceuticals (now Takeda), Merck & Co., Inc. and Sandoz Pharma AG (now Novartis) in both Europe and the United States and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School. He was born in 1965.

Shareholding: 10,000
Share rights: 143,818
ESOP's: 195,107

Donato Spota

Senior Vice President, Chief Financial Officer

Donato Spota joined Hansa Biopharma in 2019 and brings more than 20 years of pharmaceutical industry experience in international environments, including strategic finance, business development, investor relations and international capital markets transactions to the company. Prior to joining Hansa, Donato Spota served as Chief Financial Officer at Basilea Pharmaceutica AG. He holds a degree in Information Technology from the Swiss BBT (Bundesamt für Berufsbildung und Technologie) and a master’s degree in business administration from the Hochschule für Wirtschaft und Umwelt Nürtingen-Geislingen. He was born in 1971.

Shareholding: –
Share rights: 52,073
ESOP's: 106,842

Christian Kjellman

Senior Vice President, Chief Scientific Officer and Chief Operating Officer

Christian Kjellman is an experienced researcher and senior executive that joined Hansa Biopharma in 2008. Last year, Christian expanded his duties within Hansa Biopharma, serving as Chief Operating Officer as well as continuing to serve as Chief Scientific Officer. Christian has previously served as Senior Scientist at BioInvent AB focusing on novel target evaluation and antibody technology. Prior to that, he functioned as Head of Research at the biopharmaceutical development company Cartela AB, mainly focusing on novel drug target evaluation. He has extensive research experience in cell and molecular biology and as an Assistant Professor in Molecular Genetics at Lund University. Christian Kjellman holds a M.Sc. in Chemical Biology and a Ph.D. in Tumour Immunology from Lund University. He was born in 1967.

Shareholding: –
Share rights: 58,440
ESOP's: 64,380

Henk Doude van Troostwijk

Senior Vice President, Chief Commercial Officer

Henk Doude van Troostwijk has extensive management experience in sales and marketing in the areas of transplantation and orphan drugs. Before joining Hansa Biopharma in 2016, Henk Doude van Troostwijk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk Doude van Troostwijk holds an MBA from Henley Management College at the University of Reading, UK. He was born in 1965.

Shareholding: -
Share rights: 33,817
ESOP's: 51,231

Achim Kaufhold

Senior Vice President, Chief Medical Officer

Achim Kaufhold, M.D.,  joined Hansa Biopharma in June 2020. He is a highly experienced senior leader in immunology, infectious diseases and oncology. He has extensive international experience within the biotech and pharmaceutical industry and has a successful track record in taking products from early discovery through development and to the market. He has served in senior executive positions in general management, product and business development. He served as CEO of Affitech and Pharmexa (both companies merged), CMO of companies such as Basilea Pharmaceutica, Pharmexa, Chiron (acquired by Novartis) and Berna Biotech (now Johnson & Johnson). Prior to that, he was heading the worldwide clinical development of the pediatric vaccine portfolio of GlaxoSmithKline. Achim Kaufhold graduated as a Doctor of Medicine from the University of Cologne and holds a professorship in Medical Microbiology and Infectious Diseases at the University of Aachen, Germany. He was born in 1957.

Shareholding: -
Share rights: 20,000
ESOP's: 30,000

Anne Säfström Lanner

Senior Vice President, Chief Human Resources Officer

Anne Säfström Lanner joined Hansa Biopharma in January 2019 and brings 15 years of HR experience in international environments. Prior to joining Hansa, Anne Säfström Lanner served at European Spallation Source (ESS), a European multi-disciplinary research facility and at Cellavision, a provider of digital solutions for medical microscopy within hematology. She has held positions both as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from fast growing start-up international companies. Anne holds a Bachelor of Social Science in Human Resource Management, focusing on strategic organizational development & leadership, from Lund University. She was born in 1969.

Shareholding: 610
Share rights: 49,618
ESOP's: 32,000

Board of Directors

Ulf Wiinberg

Member and Chairman of the Board since 2016

Member of the Board and acting CEO during the period from November 9, 2017 until March 20, 2018. Ulf Wiinberg is an experienced healthcare industry professional who has served on the boards of several healthcare industry associations. At Wyeth, he has been both President of the Global consumer health care business and President of the European pharma business. He also held the position of CEO of H Lundbeck A/S, a pharmaceutical Company specialized in psychiatric and neurological disorders, for several years. Ulf is the CEO of X-Vax Therapeutic Inc, a Company seeking to develop a vaccine against Herpes, as well as a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical Company UCB. He is also chairman of the board of Sigrid Therapeutics AB. He was born in 1958.

Ulf is member of Hansa Biopharma’s Remuneration Committee and Scientific Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 114,900

Birgit Stattin Norinder

Member of the Board since 2012

Chairman of the Board during the periods September 2014 until June 2016 as well as November 9, 2017 until March 20,2018. Birgit Stattin Norinder has extensive experience from international pharmaceutical and biotechnology companies in Sweden, the USA and the United Kingdom. She has managed several research and development departments, resulting in a number of novel and approved pharmaceuticals. Amongst many things she has served as CEO and Chairman at Prolifix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit Stattin Norinder has also held several board and chairman positions of European biotechnology companies. She is a member of the board of AddLife AB and Jettesta AB and as of May 2020, Oasmia Pharmaceutical AB. Chairman of the Board of Hansa Biopharma 2014-2016. Birgit Stattin Norinder holds an M.Sc. in Pharmacy from Uppsala University. She was born in 1948.

Birgit Stattin Norinder is member of Hansa Biopharma’s Scientific Committee, and Chairman of the Remuneration Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 42,205

Mats Blom

Member of the board since 2019

Mats Blom has extensive managerial experience and is Chief Financial Officer (CFO) of NorthSea Therapeutics. He has served as CFO of Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats Blom has held CFO positions at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats is a board member of Auris Medical AG and Pephexia A/S. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona. He was born in 1965.

Mats is member of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 1,000

Eva Nilsagård

Member of the board since 2019

Eva Nilsagård is founder and currently CEO of Nilsagård Consulting AB. She has served as CFO of OptiGroup, Vitrolife and Plastal, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the Audit Committee of Addlife, Bufab, Irras, Nimbus Group and Xbrane Biopharma, chairman of Spermosens and board member of SEK (Swedish Export Credit Company). Eva Nilsagård has more than ten years of experience as a mentor for young female managers with high potential. Eva Nilsagård holds an Executive MBA in Economics and a BSc in accounting and finance from School of Business, Economics and Law in Gothenburg. She was born in 1964.

Eva is Chairman of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 3,000

Anders Gersel Pedersen

Member of the Board since 2018

Anders Gersel Pedersen has a long experience in the international pharmaceutical industry. Following his degree in medicine and research fellow positions at Copenhagen hospitals, he worked for Eli Lilly for 11 years. In January 2000 he joined H. Lundbeck A/S in Denmark and most recently served as Executive Vice President of the Research & Development organization, responsible for the discovery and development of the product pipeline from preclinical activities to post-launch marketing studies. He is a member of the Danish Society of Internal Medicine and serves on the supervisory boards of Avillion LLP, Bavarian Nordic A/S, and Genmab A/S. Anders Gersel Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. He was born in 1951.

Anders is Chairman of Hansa Biopharma’s Scientific Committee, and member of the Remuneration Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 2,500

Andreas Eggert

Member of the Board since 2018

Andreas Eggert has more than 25 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He is the Chief Operating Officer at X-Vax Technology Inc. in the U.S. Previously, he served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and Member of the Corporate Management Committee at H. Lundbeck A/S in Denmark, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served as Vice President & Global Business Manager at Wyeth/Pfizer in the U.S. He held several senior commercial positions for Wyeth in the US, Japan and in Germany. Andreas also was a Management Consultant at A.T. Kearney. Andreas Eggert holds an MBA from Azusa Pacific University. He was born in 1967.

Andreas is member of Hansa Biopharma’s Audit Committee and Scientific Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 5,500